lc-3

Albendazole (SKF-62979) is used as a drug indicated for the treatment of a variety of worm infestations.

LC3-mHTT-IN-AN2 (5,7-Dihydroxy-4-phenylcoumarin) is found in the plant Passiflora serratodigitata with the antibacterial activity.

LC3-mHTT-IN-AN1 is a mHTT-LC3 linker compound that interacts with both mutant huntingtin protein (mHTT) and LC3B. LC3-mHTT-IN-AN1 targeted mHTT to autophagosomes reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons.

Retro-2 (2-{[(5-methyl-2-thienyl)methylene]amino}) is a plant toxin ricin inhibitor, itprotects HeLa cells against Ricin, Stx1 and Stx2, selectively blocks retrograde toxin trafficking at the early endosome-TGN (trans-Golgi network) interface.

C18:0 Lc3 Ceramide (d18:1/18:0) is a ganglioside.

SLC-391 is a selective, orally active AXL inhibitor with an IC50 of 9.6 nM [SLC-391 exhibits antiviral activity].

Tigulixostat (LC350189) is a novel xanthine oxidase inhibitor (XOI) that reduces uric acid production and may be used in studies of gout-related diseases.

Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- (4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]butanoic acid) is a Cereblon ligand with alkyl linker and terminal acid for onward chemistry.

MMV665916 is a quinazolinedione derivative that is an antimalarial agent. MMV665916 shows remarkable antiplasmodial activity against P. falciparum FcB1 strain with EC 50 value of 0.4 μM and presents the high selectivity index (SI>250) [1].

NVS-ZP7-4 is a inhibitor of Zinc transporter SLC39A7 (ZIP7).

SLC13A5-IN-1 is a selective inhibitor of the sodium-citrate co-transporter (SLC13A5) that completely blocks the uptake of 14C-citrate, with an IC50 of 0.022 μM in HepG2 cells.

LC3B recruiter 1 (compound 33R) is an LC3B recruiting fragment. It directly interacts with LC3B, exhibiting a Kd value of 2.87 µM.

LC3B ligand 1 is the target protein ligand for PROTAC, and it can be utilized in the synthesis of PROTACCDK9 autophagic degrader 1.

LC3B recruiter 2 (34R) is an LC3B recruiting agent incorporated into the autophagy-lysosome pathway degradation system (ATTEC, Autophagy-Tethering Compounds), with a direct binding affinity for LC3B. It connects via a linker to the CDK9 inhibitor SNS-032, creating an ATTEC capable of targeting and degrading the CDK9 and Cyclin T1 complex, while also inhibiting them. Consequently, LC3B recruiter 2 exerts its function through an LC3B-dependent autophagy-lysosome pathway, interfering with the cancer cell cycle progression, thereby demonstrating antitumor activity.

LC3B ligand 2 is a ligand for E3 ubiquitin ligase. It can be connected to a target protein ligand through a linker, forming PROTACPCSK9 autophagic degrader 2. PROTACs are capable of inducing the ubiquitination and degradation of oncogenic proteins.

Pomalidomide 4'-alkylC3-azide (compound 2b) is an E3 ligase ligand-linker conjugate that includes a cereblon (CRBN) ligand derived from Pomalidomide and a linker. It is utilized in the synthesis of PROTACs.

SLC3037 is an NLRP3 inhibitor that prevents the binding or oligomerization of NLRP3 with NEK7, thereby inhibiting inflammasome activation triggered by MSU and other activators. It is suitable for research related to gout, cardiovascular diseases, metabolic syndrome, or neurodegenerative diseases.

LLC355 is a discoidin domain receptor 1 (DDR1) ATTEC degrader. It efficiently degrades DDR1 protein, with a DC50 value of 150.8 nM in non-small cell lung cancer NCI-H23 cells. LLC355 induces DDR1 degradation via lysosome-mediated autophagy and effectively inhibits the tumorigenicity, migration, and invasion of cancer cells.

TLC 388, a DNA topoisomerase I inhibitor, is used potentially for the treatment of Renal carcinoma and Hepatocellular carcinoma

PFK-158 is an effective and specific inhibitor PFKFB3.

Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC1-PEG3-alkylC3 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

Functionalized von-Hippel-Lindau protein ligand (VHL) for research and development; incorporates an E3 ligase ligand plus alkylC3 linker with terminal carboxylic acid ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules.

Functionalized von-Hippel-Lindau (VHL) protein ligand for PROTAC research and development; incorporates an E3 ligase ligand plus an alkyl C3 linker and terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

Arecaidine hydrochloride may have carcinogenesis.